RxDoctor Payments Data

Sharon Gossman, APRN

Nurse Practitioner · Neligh, NENPI 1477539898

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 60 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$384
  • Pfizer$187
  • Novo Nordisk$90
  • Viatris Specialty LLC$78
  • Mylan Specialty L.p.$76
  • Lilly USA, LLC$59
  • plus $142 from 9 others

What the payments were for

  • Food & beverage$1,017100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 70th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$119,601
Medicare patients
159
Services billed
16,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$53,970
EliquisApixaban43$36,003
Repatha SureclickEvolocumab48$33,409
LinzessLinaclotide46$24,972
MounjaroTirzepatide12$19,211
XareltoRivaroxaban27$9,198
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,537
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,163
MyrbetriqMirabegron12$5,393
Bisoprolol Fumarate105$3,359
NovologInsulin Aspart11$2,995
Losartan Potassium282$2,939
Levothyroxine Sodium351$2,872
Pantoprazole Sodium141$2,102
Omeprazole201$2,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$36,00343 claims
AbbVieLinzess$18$24,97246 claims
Lilly USA, LLCMounjaro$59$19,21112 claims
Novo NordiskNovolog$90$2,99511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Neligh

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →